We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Sepracor's Xopenex HFA Metered-Dose Inhaler
FDA Approves Sepracor's Xopenex HFA Metered-Dose Inhaler
May 10, 2006
The FDA has approved Sepracor’s new drug application for Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler for the treatment or prevention of bronchospasm in adults, adolescents and children age 4 and older with reversible obstructive airway disease.